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INTRODUCTION
Allergic rhinitis and asthma, recognized as immediate-type 
hypersensitivity reactions, are characterized by increased 
responsiveness of the tracheobronchial tree to a variety 
of stimuli, which may be spontaneous, allergen-related, 
or drug-induced, and the primary pathophysiological 
abnormality being bronchial wall inflammation leading to 
airway narrowing.[1-3]
The prevalence and severity of allergic asthma has been 
steadily increasing over past 20 years together with the 
number of reported cases of fatal asthma, and it affects up 
to 10% of the population of most developed countries.  [4,5] 
The disease statistics clearly necessitates the increasing 
need for drugs targeting the mechanisms involved in 
eosinophil and neutrophil activation and accumulation, 
anti-IgE therapy for the management of asthma. 
Glucocorticosteroids are the only drugs currently available 
that effectively reduce airway inflammation in asthma.[6] As 
a result there is high prevalence of usage of complementary 
and alternative medicines for treatment of this disease.[7]
Myrica esculenta Buch.Ham. (Syn. Myrica sapida, Family 
Myricaceae, commonly known as Kaiphal) is known 
traditionally in Ayurveda for the treatment of asthma 
and bronchitis.[8,9] Preliminary studies performed at our 
laboratory has established the efficacy of M. esculenta 
in decreasing bronchial hyper-responsiveness and 
bronchoconstriction through systematic studies on 
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bronchoalveolar lavage, acetyl choline and histamine-induced 
bronchospasm, and lung cytology in guinea pigs.[10,11] The 
pathophysiology of asthma involves multiple factors leading 
to hyper-responsiveness and bronchoconstriction, such 
as mast cell degranulation,[12] neurogenic dysfunction,[13] 
involvement of T-lymphocytes and eosinophils,[14,15] altered 
immunosuppressive macrophages,[16,17] overproduction 
of proinflammatory cytokines,[18,19] immunoglobulins 
(IgE, IgG, and IgD)[20] and plasma protein exudation.[21-23] 
Therefore, the present work aims to prove the antiallergic 




Aerial parts of M. esculenta were obtained from commercial 
supplier of Ahmedabad. The plant was identified and 
authenticated by Dr. Minoo Parabia, Head and Professor, 
Department of Bioscience, Veer Narmad South Gujarat 
University, Surat, Gujarat. A voucher specimen of plant 
was deposited in the herbarium of the Department of 
Bioscience, Veer Narmad South Gujarat University, Surat, 
Gujarat.
Preparation of the plant extract
The aerial parts reduced to coarse powder were macerated 
with ethanol for 48 h, filtered, and filtrate was evaporated 
under reduced pressure to obtain a dry extract. The 
ethanolic extract of M. esculenta (referred to as EtMe) was 
stored in cool and dry place and used for pharmacological 
evaluation.
Reagents
Egg albumin and aluminum hydroxide hydrate gel (alum) 
were purchased from S. D. Fine Chem Limited, India. 
Freund’s complete adjuvant emulsion, and Evans blue were 
purchased from HiMedia, India. All other chemicals used 
were of analytical grade.
Animal protocol
Swiss albino mice of either sex housed in standard 
conditions of temperature (22 6 28C), relative humidity 
(55 6 5%), and light (12 hrs light/dark cycles) were used. 
Animal studies were approved by the Institutional Animal 
Ethics Committee (protocol no 8004), as per the guidelines 
of committee for the purpose of control and supervision 
of experiments on animals (CPCSEA).
Vascular permeability induced by acetic acid[24,25]
Swiss albino mice were randomly allocated to four groups 
each containing six animals. Group I (model control), 
Group II (standard), Group III (EtMe), and Group IV 
(EtMe) received saline, indomethacin (20 mg/kg), EtMe 
(75 mg/kg), and EtMe (150 mg/kg) orally, respectively. 
Thirty minutes later, mice received an intravenous 
injection of 0.5% Evans blue saline solution (0.1 ml/10 g 
body weight) and an intraperitoneal injection of 0.6% 
acetic acid (10 ml/kg). After 20 min, the dye that leaked 
into the peritoneal cavity was collected by lavaging 
with 10 ml distilled water and was transferred to 10 ml 
volumetric flask through glass wool. To each flask, 0.1 ml 
of 0.1 N sodium hydroxide solution was added and 
volume made upto the mark with distilled water followed 
by measurement of absorbance at 610 nm (Shimadzu 
Spectrophotometer).
Allergic pleurisy
Swiss albino mice were randomly allocated to five groups 
each containing six animals: Group I (normal control), 
Group II (model control), Group III (standard), Group IV 
(EtMe), and Group V (EtMe). Active sensitization of 
Swiss albino mice was achieved with a subcutaneous 
injection of Freund’s complete adjuvant emulsion 
(100 mL) containing egg albumin (100 mg). Fourteen 
days later, mice were challenged with an intrathoracic 
injection of egg albumin (50 mL, 12.5 mg/cavity).[26,27] 
Briefly, an adapted needle was inserted into the right 
side of the thoracic cavity of egg albumin sensitized 
animals to permit the intrapleural administration of egg 
albumin diluted in sterile pyrogen free saline (50 mL). At 
24 h after the stimulus, mice were anesthetized and their 
thoracic cavities were rinsed with 1 mL phosphate buffer 
saline containing 10 mM EDTA, pH 7.4. Total leukocyte 
counts were made with an automated cell counter (Cell 
Dyn 3200SL). Differential cell counts were made by light 
microscopy stained with Leishman’s stain. Groups IV 
and V animals fasted overnight and received EtMe 
(75 mg/kg) and EtMe (150 mg/kg) orally 1 h before 
stimulation. Group II animals were similarly treated with 
vehicle alone. In Group III, dexamethasone was given 
intraperitoneally (2 mg/kg) 24 and 1 h before stimulation.
Statistical analysis
The results of various studies were expressed as mean 6 SEM 
and analyzed statistically using one-way ANOVA with 
Dunnett post hoc test to find out the level of significance. 
Data were considered statistically significant at P , 0.05.76   J Young Pharm Vol 2 / No 1
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RESULTS
Effect of EtMe on vascular permeability induced by 
acetic acid
Pretreatment with EtMe (75 mg/kg) and EtMe (150 mg/  kg) 
significantly inhibited the rise in plasma exudation (57.12% 
and 59.77% inhibition) induced by acetic acid in mice as 
compared to the control group. Indomethacin (20 mg/kg) 
also significantly inhibited the exudation (70.69%) [Table 1].
Effect of EtMe on allergic pleurisy
Twenty-four hours after the intrathoracic injection 
of egg albumin, an intense accumulation of total and 
differential leukocytes was observed in sensitized as 
compared to the control group. Dexamethasone pre-
treatment (2 mg/  kg, i.p.) significantly inhibited the influx 
of total and differential leukocytes as compared to the 
sensitized group. The oral pretreatment with EtMe 
(75 mg/kg and 150 mg/  kg, po) markedly inhibited the 
eosinophil accumulation as compared to the control 
group and this inhibition was selective for decrease in the 
number of eosinophils. Conversely, the number of total 
leukocytes, lymphocyte, monocytes, and neutrophils was 
not significantly affected on oral pre-treatment with EtMe 
(75 mg/kg and 150 mg/kg, po) [Table 2].
DISCUSSION
Allergic processes are complex disorders in which 
inflammatory and immunological mechanisms are 
involved. Bronchial asthma is one such allergic process 
characterized by inflammation of the airways usually 
accompanied by increased vascular permeability, resulting 
in plasma exudation. Plasma protein leakage has been 
implicated to play a role in the induction of a thickened, 
engorged, and edematous airway wall, resulting in the 
airway luminal narrowing correlating with bronchial 
hyper-reactivity and airway inflammation.[28,29] It is also 
possible that the plasma exudates may readily pass the 
inflamed mucosa and reach the airway lumen through 
leaky epithelium, thus compromising epithelial integrity 
and reducing ciliary function and mucus clearance.[30,31] 
It is also reported that increased vascular permeability 
is associated with bronchial inflammation and airway 
hyper-responsiveness in a murine model of asthma.  [32,33] 
Consistent with these observations, we have found 
that amounts of plasma extravasation were greatly 
enhanced in a murine model of allergic airway disease. 
Interestingly, administration of EtMe inhibited vascular 
permeability increase thereby inhibiting vascular leakage 
resulting in decreased airway inflammation and airway 
hyper-responsiveness.
Additionally, an important causative factor of allergic 
disease is eosinophilic inflammation.[34,35] The triggering 
and regulation of eosinophil accumulation in allergic 
inflammation depend on the release of cytokines and 
chemokines such as interleukin-4 (IL-4), IL-5 and CCL11/
eotaxin in response to an antigen challenge.[36,37] Among the 
C-C chemokines, CCL11/eotaxin, an eosinophil-specific 
chemoattractant, is one of the most important mediators 
of allergic inflammation, with a potent and selective 
effect in mobilizing eosinophils from bone marrow to 
the blood.[37-40] To participate in the allergic inflammatory 
response, eosinophil must migrate from the circulation 
to the airway.[41,42] Circulating eosinophils migrate to 
the airways by the phenomenon of cell rolling, through 
interaction with P-selectin, and eventually adhere to the 
endothelium through the binding of integrins to adhesion 
proteins, vascular cell adhesion molecule 1 (VCAM 1) 
and intercellular adhesion molecule 1 (ICAM 1). As 
eosinophils enter the matrix of the membrane, their 
survival is prolonged by IL-5. The cytoplasmic granules of 
eosinophils have a crystalloid core of major basic protein 
and a matrix of eosinophil cationic protein, eosinophil-
Table 2: Effect of EtMe on cell counts in allergic pleurisy
Group Total leukocyte Neutrophil Lymphocyte Eosinophil Monocyte
Control 3575 6 411 1857.75 6 291.39 1567.25 6 169.71 65.5 6 14.06 83.25 6 17.95
Sensitized 5225 6 383.78* 3072.75 6 264.34* 2002 6 108.44 145 6 27.54* 111.75 6 5.63*
Dexamethasone (2 mg/kg) 2550 6 413.32@ 1273.5 6 202.37@ 1182.25 6 187.97@ 32.75 6 9.3@ 61.5 6 20.36
EtMe (75 mg/kg)  4425 6 968.14 2630.5 6 761.26 1679.5 6 219.2 51.75 6 8.87@ 63.25 6 12.92
EtMe (150 mg/kg)  4423 6 259.41 2319.25 6 277.2@ 1938 6 160.67 67 6 14.29@ 100.75 6 15.96
Statistical analysis by one-way ANOVA with the Dunnett post hoc test; values are mean 6  SEM, n 5  6 in each group; significantly different from control group; *P , 0.05 
(one‑way ANOVA); significantly different from sensitized group; @P , 0.05 (one-way ANOVA with the Dunnett post hoc test)
Table 1: Effect of EtMe on vascular permeability induced 
by acetic acid




Control 1.474 6 0.121 -
Standard (Indomethacin, 20 mg/kg) 0.432 6  0.14* 70.69
EtMe (75 mg/kg)  0.632 6  0.151* 57.12
EtMe (150 mg/kg)  0.593 6  0.222* 59.77
Statistical analysis by one way ANOVA with Dunnett post hoc test; values are 
mean 6 SEM; n 5  6 in each group; significantly different from control group; *P , 0.05J Young Pharm Vol 2 / No 1  77
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derived neurotoxin, and eosinophil peroxidase that are 
released on activation. Major basic protein and eosinophil 
cationic protein have profound cytotoxic effects on the 
airway epithelium,[43] and for this reason, eosinophils are 
often regarded as the primary effector cells in asthma. 
The modulation of eosinophil accumulation is one of the 
main targets for the discovery of anti-allergic compounds 
because of its potential tissue damaging effects. Above 
facts were further substantiated by observing the potential 
effect of EtMe which produced a pronounced inhibition 
of eosinophil accumulation in allergic pleurisy, hence 
decreasing allergic inflammation.
CONCLUSION
Overall data from our experimental studies suggest that 
ethanolic extract of M. esculenta possesses significant 
anti-allergic and anti-inflammatory activity and may 
be useful in the treatment of allergic disorders such as 
allergic asthma and allergic rhinitis by decreasing bronchial 
hyper-responsiveness.
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